The company buys in a PI3Kα and mTOR combo.
ApexOnco Front Page
Recent articles
Gilead opting against IDE397 is still good news for Ideaya.
Gilead links up with Tubulis, while GSK taps BioNTech’s partner DualityBio.
The US subsidiary of South Korea’s HLB will take on the selective FGFR2 inhibitor.
Phase 3 development plans for BNT327 and ivonescimab start to diverge.
The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.
